Want to join the conversation?
$GILD said that total 2Q16 HIV and other anti-viral revenues in the US were $2.2Bil, up 11% sequentially. Genvoya, the most prescribed HIV regimen since the introduction of Atripla, had nearly double the revenue during the quarter. The company estimates that approx. 60,000-70,000 were using Truvada in 2Q16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?